Table 1.
Patient characteristics of DAA failure patients with rare GT (n = 60) at study inclusion.
| Rare GT1 n = 6 |
Rare GT2 n = 2 |
Rare GT3 n = 15 |
Rare GT4 n = 28 |
GT5a n = 2 |
Rare GT6 n = 7 |
|
|---|---|---|---|---|---|---|
| Mean age, years | 55.3 | 54.7 | 46.1 | 58.2 | 63.6 | 58.3 |
| Male sex, n (%) | 4 (67) | 1 (50) | 14 (93) | 23 (93%) | 1 (50) | 7 (100) |
| Cirrhosis, n (%) | 1 (17) | 0 (0) | 7 (47) | 10 (40) n = 25 | 0 (0) | 1 (14) |
| HCC, n (%) | 0 (0) | 0 (0) | 0 (0) | 2 (8) n = 25 | 0 (0) | 1 (14) |
| Prior IFN-experience, n (%) | 3 (60) n = 5 | 1 (50) | 5 (46) n = 11 | 11 (48) n = 23 | 0 (0) | 0 (0) n = 6 |
| DAA treatment history, n (%) | ||||||
| 2D/3D PrOD (PTV/r/OBV ± DSV) | 1 (17) | — | — | 6 (21) | — | 2 (29) |
| GZR/EBR | 1 (17) | — | 1 (7%) | 2 (7) | — | 1 (13) |
| LD/VSOF | 4 (66) | — | 1 (7%) | 12 (43) | — | 2 (29) |
| SOF/RBV | — | 2 (100) | — | 1 (4) | 1 (50) | — |
| DCV/SOF | — | — | 6 (40) | 4 (14) | — | — |
| VEL/SOF | — | — | 4 (26) | 2 (7) | 1 (50) | 2 (29) |
| G/P | — | — | 3 (20) | 1 (4) | — | — |
DCV/SOF, daclatasvir/sofosbuvir; EBR/GZR, elbasvir/grazoprevir; LDV/SOF, ledipasvir/sofosbuvir; G/P, glecaprevir/pibrentasvir; (pegylated); HCC, hepatocellular cellular carcinoma; IFN, interferon; 2D/3D, paritaprevir/r/ombitasvir ± dasabuvir; RBV, ribavirin; VEL/SOF, velpatasvir/sofosbuvir.